Supplementary Data from Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer

Kankan Cao,Guodong Zhang,Moran Yang,Yiying Wang,Mengdi He,Chen Zhang,Yan Huang,Jiaqi Lu,Haiou Liu

DOI: https://doi.org/10.1158/0008-5472.23627639.v1

2023-01-01

Abstract:Materials and Methods: Supplementary Figure S1 to S14 for multiple supplementary figures

What problem does this paper attempt to address?

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells Against Solid Tumors

Wenqun Zhong,Zhang Xiao,Zhiyuan Qin,Jingbo Yang,Yi Wen,Ziyan Yu,Yumei Li,Neil C. Sheppard,Serge Y. Fuchs,Xiaowei Xu,Meenhard Herlyn,Carl H. June,Ellen Puré,Wei Guo

DOI: https://doi.org/10.1158/0008-5472.23952936.v1

2023-01-01

Abstract:Supplementary Figures and Figure Legends
Attenuation of sialylation augments antitumor immunity and improves response to immunotherapy in ovarian cancer

Kankan Cao,Guodong Zhang,Moran Yang,Yiying Wang,Mengdi He,Chen Zhang,Yan Huang,Jiaqi Lu,Haiou Liu

DOI: https://doi.org/10.1158/0008-5472.can-22-3260

IF: 11.2

2023-05-14

Cancer Research

Abstract:Aberrant sialylation functions as an important modulator of all steps of malignant transformation. Therefore, targeting sialylation regulators, such as sialyltransferases and neuraminidases, is a potential strategy for treating cancer. Here, we found that elevated α2,3-sialyltransferase III (St3gal3) was associated with dismal prognosis in high-grade serous ovarian carcinoma (HGSC). St3gal3 knockdown antagonized subcutaneous tumor growth in immunocompetent, but not immunodeficient mice, with enhanced accumulation of functional CD8+ T cells and anti-tumor immune gene signatures. St3gal3 knockdown inhibited intraperitoneal tumor growth and repolarized tumor-associated macrophages from a pro-tumorigenic M2-like to a tumor-suppressive M1-like phenotype. In vitro, St3gal3 knockdown tumor cells guided bone marrow-derived macrophages (BMDM) toward the M1-like phenotype under both direct contact and distant transwell co-culture conditions. Depletion of macrophages rescued the suppressed tumor growth induced by St3gal3 knockdown and completely suppressed infiltration of functional CD8+ T cells that rely on macrophage-derived CXCL10. St3gal3 engendered an immunosuppressive HGSC microenvironment characterized by an abundance of pro-tumorigenic macrophages and reduced cytotoxic T cell infiltration. In vivo, St3gal3 knockdown improved effectiveness of dual immune checkpoint blockade (ICB) with αPD-1 and αCTLA-4 antibodies. Preclinical inhibition of sialylation with ambroxol resulted in decreased tumor growth and prolonged the survival of tumor-bearing mice, which was enhanced by the addition of dual ICB. These findings indicate that altered sialylation induced by St3gal3 upregulation promotes a tumor suppressive microenvironment in HGSC and targeting α2,3-sialylation may reprogram the immunosuppressive tumor microenvironment and improve the efficacy of immunotherapy.

oncology
Supplementary Data 1 from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer

Tao Jiang,Qiqi Jin,Jiahao Wang,Fengying Wu,Jian Chen,Gongyan Chen,Yunchao Huang,Jianhua Chen,Ying Cheng,QiMing Wang,Yueyin Pan,Jianying Zhou,Jianhua Shi,Xingxiang Xu,LiZhu Lin,Wei Zhang,Yiping Zhang,Yunpeng Liu,Yong Fang,Jifeng Feng,Zhehai Wang,Sheng Hu,Jian Fang,Yongqian Shu,Jiuwei Cui,Yi Hu,Wenxiu Yao,Xingya Li,Xiaoyan Lin,Rui Wang,Yongsheng Wang,Wei Shi,Gaohua Feng,Jun Ni,Beibei Mao,Dandan Ren,Huaibo Sun,Henghui Zhang,Luonan Chen,Caicun Zhou,Shengxiang Ren

DOI: https://doi.org/10.1158/1078-0432.23791953.v1

2023-01-01

Abstract:Supplementary Materials
Supplementary Tables from Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity

Dapeng Hao,Jie Liu,Meng Chen,Jingjing Li,Li Wang,Xiaobo Li,Qi Zhao,Lijun Di

DOI: https://doi.org/10.1158/1078-0432.22470641.v1

2023-01-01

Abstract:Supplementary Table 1 and Supplementary Table 2
Supplementary Data from Targeting Fc Receptor-Mediated Effects and the “don't Eat Me” Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer

Tian Liu,Bo Xu,Kun‐Yu Teng,Mi‐Yeon Song,Zheng Zhu,Yuqing Chen,Jing Wang,Jianying Zhang,Feng Mao,Balveen Kaur,Lorna Rodriguez,Michael A. Caligiuri,Jianhua Yu

DOI: https://doi.org/10.1158/1078-0432.22483347.v1

2023-01-01

Abstract:All supplementary data: supplementary figures s1-s13 and table s1
Supplementary Data from Genetically Defined Syngeneic Mouse Models of Ovarian Cancer As Tools for the Discovery of Combination Immunotherapy

Sonia Iyer,Shuang Zhang,Simge Yucel,Heiko Horn,Sean G. Smith,Ferenc Reinhardt,Esmée P. Hoefsmit,Bimarzhan Assatova,Julia Casado,Marie-Charlotte Meinsohn,M. Inmaculada Barrasa,George W. Bell,Fernando Pérez‐Villatoro,Kaisa Huhtinen,Johanna Hynninen,Jaana Oikkonen,Pamoda M. Galhenage,Shailja Pathania,Paula T. Hammond,Benjamin G. Neel,Anniina Färkkilä,David Pépin,Robert A. Weinberg

DOI: https://doi.org/10.1158/2159-8290.22536206.v1

2023-01-01

Abstract:Supplementary data includes suppl methods, FigS1-7ï¼Œ Table S1-6, Methods Tables 1-5
Supplementary Data from A Paradigm of Cancer Immunotherapy Based on 2-[<sup>18</sup>F]FDG and Anti–PD-L1 mAb Combination to Enhance the Antitumor Effect

Xuejun Wen,Changrong Shi,Xinying Zeng,Liang Zhao,Lanlin Yao,Zhida Liu,Lixia Feng,Deliang Zhang,Jinxiong Huang,Yesen Li,Qin Lin,Haojun Chen,Rongqiang Zhuang,Xiaoyuan Chen,Xianzhong Zhang,Zhide Guo

DOI: https://doi.org/10.1158/1078-0432.22486374

2023-01-01

Abstract:Supplementary Data from A Paradigm of Cancer Immunotherapy Based on 2-[<sup>18</sup>F]FDG and Anti–PD-L1 mAb Combination to Enhance the Antitumor Effect
Supplementary Data from XCL1/Glypican-3 Fusion Gene Immunization Generates Potent Antitumor Cellular Immunity and Enhances Anti–PD-1 Efficacy

Kun Chen,Zhiyuan Wu,Hong Zhao,Yanmei Wang,Yutong Ge,Dongmei Wang,Zhengjiang Li,Changming An,Yuying Liu,Feifei Wang,Xinyu Bi,Hongying Wang,Jianqiang Cai,Chunhong Ma,Chunfeng Qu

DOI: https://doi.org/10.1158/2326-6066.22543440

2023-01-01

Abstract:Supplementary Tables 1-2 and Supplementary Figures 1-8
Supplementary Data from Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer

Lin Cheng,Shichao Zhou,Shaoqing Zhou,Kaixuan Shi,Yan Cheng,Mei-Chun Cai,Kaiyan Ye,Lifeng Lin,Zhenfeng Zhang,Chenqiang Jia,Huaijiang Xiang,Jingyu Zang,Meiying Zhang,Xia Yin,Ying Li,Wen Di,Guanglei Zhuang,Li Tan

DOI: https://doi.org/10.1158/0008-5472.22432443

2023-01-01

Abstract:Supplementary Data from Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer
Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Zhiliang Ma,Wen Li,Shinichi Yoshiya,Yong Xu,Masaki Hara,Yosif El‐Darawish,Tzvetanka Markova,Kyosuke Yamanishi,Hiromichi Yamanishi,Hideaki Tahara,Yoshimasa Tanaka,Haruki Okamura

DOI: https://doi.org/10.1158/1078-0432.22459815.v1

2023-01-01

Abstract:Cytotoxic activity exhibited by PECs from pre-implanted mice receiving immune checkpoint blockade and/or IL-18
Supplemental Data from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Jing Huang,Lin Xiao,Xiaoting Gong,Wenwei Shao,Yanhui Yin,Qinyuan Liao,Yang Meng,Yingmei Zhang,Dalong Ma,Xiaoyan Qiu

DOI: https://doi.org/10.1158/0008-5472.22402070.v1

2023-01-01

Abstract:Supplemental materials and methods and legends for all supplemental figures.
Additional File 7 of Suppressive Stroma-Immune Prognostic Signature Impedes Immunotherapy in Ovarian Cancer and Can Be Reversed by PDGFRB Inhibitors

Dong Yang,Mei-Han Duan,Qiu-Er Yuan,Zhiling Li,Chuanghua Luo,Lan-Yue Cui,Lichao Li,Ying Xiao,Xianying Zhu,Hai-Liang Zhang,Feng Gao,Guochen Liu,Rong Deng,Jun‐Dong Li,Xiao‐Feng Zhu

DOI: https://doi.org/10.6084/m9.figshare.24077055

2023-01-01

Abstract:Additional file 7: Table S6. qPCR primers.
Supplementary Data from Efficient Tumor Clearance and Diversified Immunity Through Neoepitope Vaccines and Combinatorial Immunotherapy

Karin L. Lee,Stephen C. Benz,Kristin C. Hicks,Andrew Nguyen,Sofia R. Gameiro,Claudia Palena,J. Zachary Sanborn,Zhen Su,Peter Ordentlich,Lars Rohlin,John H. Lee,Shahrooz Rabizadeh,Patrick Soon‐Shiong,Kayvan Niazi,Jeffrey Schlom,Duane H. Hamilton

DOI: https://doi.org/10.1158/2326-6066.22542444

2023-01-01

Abstract:Supplementary figures and tables
Supplementary Data from Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer

Shuang Zhang,Sonia Iyer,Hao Ran,Igor Dolgalev,Shengqing Gu,Wei,Connor J.R. Foster,Cynthia A. Loomis,Narciso Olvera,Fanny Dao,Douglas A. Levine,Robert A. Weinberg,Benjamin G. Neel

DOI: https://doi.org/10.1158/2159-8290.22536016.v1

2023-01-01

Abstract:Supplementary data includes suppl methods, FigS1-8ï¼Œ Table S1-3
Supplementary Data from Human Monoclonal Antibodies to Sialyl-Lewisa (CA19.9) with Potent CDC, ADCC, and Antitumor Activity

Ritsuko Sawada,Shu-Man Sun,Xiaohong Wu,Feng Hong,Govind Ragupathi,Philip O. Livingston,Wolfgang W. Scholz

DOI: https://doi.org/10.1158/1078-0432.22444706

2023-01-01

Abstract:Supplementary Figure S1; Supplementary Tables S1-S2.
Supplementary Data from Targeted Delivery of Tumor Antigens to Activated Dendritic Cells Via CD11c Molecules Induces Potent Antitumor Immunity in Mice

Huafeng Wei,Suhui Wang,David Zhang,Sheng Hou,Weizhu Qian,Bohua Li,Haipeng Guo,Geng Kou,Jian He,Hao Wang,Yajun Guo

DOI: https://doi.org/10.1158/1078-0432.22440507

2023-01-01

Abstract:Supplementary Data from Targeted Delivery of Tumor Antigens to Activated Dendritic Cells via CD11c Molecules Induces Potent Antitumor Immunity in Mice
Supplementary Table from Characterization of Immune-Related Alternative Polyadenylation Events in Cancer Immunotherapy

Gaoyang Wang,Zuozhong Xie,Juan Su,Meishan Chen,Yanhua Du,Qian Gao,Guanxiong Zhang,Hailun Zhang,Xiang Chen,Hong Liu,Leng Han,Youqiong Ye

DOI: https://doi.org/10.1158/0008-5472.22432662

2023-01-01

Abstract:Supplementary Table from Characterization of Immune-Related Alternative Polyadenylation Events in Cancer Immunotherapy
Supplementary Data from Regorafenib Promotes Antitumor Immunity Via Inhibiting PD-L1 and IDO1 Expression in Melanoma

Rui-Yan Wu,Peng-Fei Kong,Liang-Ping Xia,Yun Huang,Zhi-Ling Li,Yun-Yun Tang,Yu-Hong Chen,Xuan Li,Ravichandran Senthilkumar,Hai-Liang Zhang,Ting Sun,Xue-Lian Xu,Yan Yu,Jia Mai,Xiao-Dan Peng,Dong Yang,Li-Huan Zhou,Gong-Kan Feng,Rong Deng,Xiao-Feng Zhu

DOI: https://doi.org/10.1158/1078-0432.22471275.v1

2023-01-01

Abstract:Supplementary Figures + Supplementary Datas
Supplementary Data from Targeting Ferroptosis-Elicited Inflammation Suppresses Hepatocellular Carcinoma Metastasis and Enhances Sorafenib Efficacy

Ming Mu,Chun-Xiang Huang,Chenxu Qu,P. Li,X. Wu,Wudexin Yao,Chu Shen,Ruxun Huang,Chao-Chao Wan,Zhi-Wei Jian,Limin Zheng,Ruiqi Wu,Xiang‐Ming Lao,Dong‐Ming Kuang

DOI: https://doi.org/10.1158/0008-5472.25415352

2024-01-01

Abstract:Supplementary Figures and Tables

Supplementary Data from Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells Against Solid Tumors

Attenuation of sialylation augments antitumor immunity and improves response to immunotherapy in ovarian cancer

Supplementary Data 1 from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer

Supplementary Tables from Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity

Supplementary Data from Targeting Fc Receptor-Mediated Effects and the “don't Eat Me” Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer

Supplementary Data from Genetically Defined Syngeneic Mouse Models of Ovarian Cancer As Tools for the Discovery of Combination Immunotherapy

Supplementary Data from A Paradigm of Cancer Immunotherapy Based on 2-[&lt;sup&gt;18&lt;/sup&gt;F]FDG and Anti–PD-L1 mAb Combination to Enhance the Antitumor Effect

Supplementary Data from XCL1/Glypican-3 Fusion Gene Immunization Generates Potent Antitumor Cellular Immunity and Enhances Anti–PD-1 Efficacy

Supplementary Data from Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer

Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Supplemental Data from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Additional File 7 of Suppressive Stroma-Immune Prognostic Signature Impedes Immunotherapy in Ovarian Cancer and Can Be Reversed by PDGFRB Inhibitors

Supplementary Data from Efficient Tumor Clearance and Diversified Immunity Through Neoepitope Vaccines and Combinatorial Immunotherapy

Supplementary Data from Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer

Supplementary Data from Human Monoclonal Antibodies to Sialyl-Lewisa (CA19.9) with Potent CDC, ADCC, and Antitumor Activity

Supplementary Data from Targeted Delivery of Tumor Antigens to Activated Dendritic Cells Via CD11c Molecules Induces Potent Antitumor Immunity in Mice

Supplementary Table from Characterization of Immune-Related Alternative Polyadenylation Events in Cancer Immunotherapy

Supplementary Data from Regorafenib Promotes Antitumor Immunity Via Inhibiting PD-L1 and IDO1 Expression in Melanoma

Supplementary Data from Targeting Ferroptosis-Elicited Inflammation Suppresses Hepatocellular Carcinoma Metastasis and Enhances Sorafenib Efficacy

Supplementary Data from A Paradigm of Cancer Immunotherapy Based on 2-[<sup>18</sup>F]FDG and Anti–PD-L1 mAb Combination to Enhance the Antitumor Effect